In light with the cardinal role of IL-1β in both NASH28 and age-related cardiometabolic diseases29, we aimed to investigate the effects of anti-IL-1β monoclonal antibody treatment on cardiac function and the potential disease altering effect in an aged non-obese mouse model of NASH, that included the evaluation of hepatic microenvironment upon IL-1β blockade. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.